Press Releases

2021

January 12, 2021
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
January 6, 2021
Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

2020

November 23, 2020
Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference
November 9, 2020
Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020
September 25, 2020
Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit
August 13, 2020
Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series
June 27, 2020
Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
June 17, 2020
Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
June 11, 2020
Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
March 23, 2020
Verve Therapeutics’ CEO Sekar Kathiresan to Speak at Wall Street Journal Health Forum

2019

October 3, 2019
Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer
October 2, 2019
Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit
September 16, 2019
Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board
May 7, 2019
Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com